Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.

Autor: Younis, Brima Musa, Mudawi Musa, Ahmed, Monnerat, Séverine, Abdelrahim Saeed, Mohammed, Awad Gasim Khalil, Eltahir, Elbashir Ahmed, Anas, Ahmed Ali, Mujahid, Noureldin, Ali, Muthoni Ouattara, Gina, Nyakaya, Godfrey M., Teshome, Samuel, Omollo, Truphosa, Ochieng, Michael, Egondi, Thaddaeus, Mmbone, Mildred, Chu, Wan-Yu, Dorlo, Thomas P. C., Zijlstra, Eduard E., Wasunna, Monique, Alvar, Jorge

Publikováno v: PLoS Neglected Tropical Diseases; 11/21/2023, Vol. 17 Issue 11, p1-20, 20p

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.

Autor: Musa AM; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan., Mbui J; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya., Mohammed R; Leishmaniasis Research and Treatment Center, University of Gondar, Gondar, Ethiopia., Olobo J; Department of Immunology and Molecular Biology, Leishmaniasis Unit, College of Health Sciences, Makerere University, Kampala, Uganda., Ritmeijer K; Médecins sans Frontières, OCA, Amsterdam, The Netherlands., Alcoba G; Médecins sans Frontières, OCG, Geneva, Switzerland., Muthoni Ouattara G; Drugs for Neglected Diseases Initiative, Nairobi, Kenya., Egondi T; Drugs for Neglected Diseases Initiative, Nairobi, Kenya., Nakanwagi P; Drugs for Neglected Diseases Initiative, Nairobi, Kenya., Omollo T; Drugs for Neglected Diseases Initiative, Nairobi, Kenya., Wasunna M; Drugs for Neglected Diseases Initiative, Nairobi, Kenya., Verrest L; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Dorlo TPC; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Musa Younis B; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan., Nour A; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan., Taha Ahmed Elmukashfi E; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan., Ismail Omer Haroun A; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan., Khalil EAG; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan., Njenga S; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya., Fikre H; Leishmaniasis Research and Treatment Center, University of Gondar, Gondar, Ethiopia., Mekonnen T; Leishmaniasis Research and Treatment Center, University of Gondar, Gondar, Ethiopia., Mersha D; Médecins sans Frontières, Abdurafi, Ethiopia., Sisay K; Médecins sans Frontières, Abdurafi, Ethiopia., Sagaki P; Amudat Hospital, Amudat Karamoja Sub-region, Uganda., Alvar J; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Solomos A; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Alves F; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Feb 08; Vol. 76 (3), pp. e1177-e1185.